Epizyme Inc
NASDAQ:EPZM
Intrinsic Value
Epizyme, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of EPZM.
Epizyme Inc's market capitalization is 247.5m USD.
EPZM stock price is 1.47 USD.
EPZM.
EPZM. Open DCF Valuation
EPZM. Open Relative Valuation
EPZM.
EPZM has positive Net Debt. This means that the company has more debt (233m USD) than cash and short-term investments (144m USD).
EPZM's long-term liabilties (284m USD) exceed its long-term assets (264m USD).
EPZM's Revenue has grown by an exceptional 63% over the past 12 months.
EPZM's ROE (Return on Equity) has significantly decreased in the last 3 years from -108% to -877%, and is approaching profitability.
EPZM's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -278% to -182%, and is approaching profitability.
EPZM has positive Gross Profit for the last twelve months.
EPZM has negative Operating Income for the last twelve months.
EPZM has negative Net Income for the last twelve months.
EPZM's ROE (Return on Equity) for the past 12 months is negative and is equal to -877%.
EPZM's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -182%.
EPZM has negative Free Cash Flow for the last twelve months.
EPZM has negative three-year average ROE (Return on Equity): -189%. The company is not efficient at transforming stockholders' equity into net income.
EPZM has negative three-year average ROIC (Return on Invested Capital): -349%. The company is not efficient at using invested capital to generate operating income.
EPZM's short-term assets (187m USD) exceed its short-term liabilties (35m USD).
EPZM's D/E (Debt to Equity) is very low and is equal to -11.48.
EPZM's Altman Z-Score is very low and is equal to -8.75.
EPZM doesn't generate enough operating income (-196m USD) to safely cover interest payments on its debt (22m USD).
Fundamental Analysis
Epizyme Inc
Balance Sheet Decomposition
Epizyme Inc
| Current Assets | 186.8m |
| Cash & Short-Term Investments | 144.4m |
| Receivables | 11.2m |
| Other Current Assets | 31.2m |
| Non-Current Assets | 77.3m |
| PP&E | 19.2m |
| Intangibles | 40.8m |
| Other Non-Current Assets | 17.4m |
| Current Liabilities | 35m |
| Accounts Payable | 5m |
| Accrued Liabilities | 30m |
| Non-Current Liabilities | 249.5m |
| Long-Term Debt | 232.9m |
| Other Non-Current Liabilities | 16.6m |
Earnings Waterfall
Epizyme Inc
|
Revenue
|
53m
USD
|
|
Cost of Revenue
|
-13m
USD
|
|
Gross Profit
|
40.1m
USD
|
|
Operating Expenses
|
-236.2m
USD
|
|
Operating Income
|
-196.2m
USD
|
|
Other Expenses
|
-11.6m
USD
|
|
Net Income
|
-207.7m
USD
|
Free Cash Flow Analysis
Epizyme Inc
EPZM Profitability Score
Profitability Due Diligence
Epizyme Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Epizyme Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
EPZM Solvency Score
Solvency Due Diligence
Epizyme Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Epizyme Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EPZM Price Targets Summary
Epizyme Inc
Ownership
EPZM Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
EPZM Price
Epizyme Inc
| Average Annual Return | 20.24% |
| Standard Deviation of Annual Returns | 109.21% |
| Max Drawdown | -98% |
| Market Capitalization | 247.5m USD |
| Shares Outstanding | 168 364 992 |
| Percentage of Shares Shorted | 2.32% |
Company Profile
Epizyme Inc
Country
Industry
Market Cap
Dividend Yield
Description
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 250 full-time employees. The company went IPO on 2013-05-31. The firm is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The firm's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. The company is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The firm is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.
You don't have any saved screeners yet
